October 19, 2021 11:03 AM EDT

Sage, Biogen head to FDA with $3.1B depression drug; Sana puts down $50M to tap Beam's CRISPR tech

Paul Schloesser

Associate Editor

Amber Tong

Weeks after announcing they would drop a pair of studies deemed unnecessary to file the depression drug zuranolone for approval, Sage and Biogen are going …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Sage, Biogen head to FDA with $3.1B depression drug; Sana puts down $50M to tap Beam's CRISPR tech

Paul Schloesser

Associate Editor

Amber Tong

Sign up to read this article for free.

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CagriSema’s weight loss data disappointed. What does Novo do next?

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

CMS explains what went into its first round of drug price negotiations

Exclusive: Florida cancer biotech raises $100M Series A

Immunology biotech Inmagene to join Nasdaq through reverse merger with what's left of Ikena

Sage, Bio­gen head to FDA with $3.1B de­pres­sion drug; Sana puts down $50M to tap Beam's CRISPR tech

Associate Editor

Sign up to read this article for free.

more like this

Sage, Biogen head to FDA with $3.1B depression drug; Sana puts down $50M to tap Beam's CRISPR tech